Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

123.34 -1.95 (-1.55%)

Streaming Delayed Price Updated: 1:12 PM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial ↗

September 24, 2025

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.

Via Stocktwits

CrowdStrike, SoFi, Clearway Energy And More: CNBC's 'Final Trades' ↗

September 19, 2025

Experts on CNBC's Halftime Report discussed top trades for the day. SoFi hit an all-time high, Clearway Energy has strong dividend yield, CrowdStrike rose sharply, and SPDR S&P Biotech ETF gained...

Via Benzinga

Topics ETFs Stocks

As the Fed Pivots, These 3 ETFs Are Positioned to Outperform ↗

September 11, 2025

With the Fed pivoting from inflation fighter to growth supporter, these three ETFs offer the best leverage to falling rates.

Via The Motley Fool

Topics ETFs Economy

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

The tariffs will impact products imported from Europe, the Trump administration said late Thursday.

Via Investor's Business Daily

Topics ETFs Government Intellectual Property

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn ↗

July 16, 2025

President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month.

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs ↗

July 08, 2025

President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."

Via Investor's Business Daily

Topics ETFs Economy Government

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages ↗

June 29, 2025

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according...

Via Stocktwits

Topics ETFs Intellectual Property

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning ↗

June 24, 2025

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Via Stocktwits

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data ↗

June 20, 2025

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Via Stocktwits

FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ ↗

June 11, 2025

Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.

Via Stocktwits

Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation ↗

May 30, 2025

Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial.

Via Stocktwits

Topics Lawsuit Regulatory Compliance

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗

May 29, 2025

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Via Stocktwits

Hedge Funds Are Building A Towering Wall Of Bets Against Stocks ↗

May 21, 2025

After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally.

Via Benzinga

Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗

May 20, 2025

The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S.

Via Investor's Business Daily

Topics ETFs Government

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗

May 19, 2025

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

Via Benzinga

Best Biotech Stocks to Buy in 2025

May 13, 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

Via MarketBeat

Topics ETFs Economy Government

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗

May 09, 2025

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024.

Via Stocktwits

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic ↗

May 05, 2025

The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August.

Via Stocktwits

Topics Economy Government

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic ↗

April 25, 2025

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.

Via Stocktwits

Topics Artificial Intelligence

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗

April 21, 2025

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.

Via Stocktwits

Topics Government Retirement Stocks

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic ↗

April 17, 2025

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

Via Stocktwits

Topics Bankruptcy

Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets ↗

April 10, 2025

Via The Motley Fool

Topics ETFs

Is It A Good Time To Trade Small Cap Biotech Stocks? - 3 Steps To Consider ↗

April 07, 2025

Large cap healthcare stocks have outperformed other sectors during the 2025 Tariff induced sell-off but they still have risks as one can see by Friday’s 5% decline.

Via Talk Markets

Topics ETFs Stocks / Equities

Biotech Weakness Ahead? ↗

April 02, 2025

Out of 50,000 posts, I’m not sure I’ve ever mentioned the sector fund XBI before, but here we are. It seems to me that this fund, representing the biotech sector, is in for some serious skidding.

Via Talk Markets

Topics ETFs

Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed. ↗

April 02, 2025

It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad.

Via Investor's Business Daily

Topics Economy Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.